– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints –...
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more...
-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with...
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady...
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive...
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAMEIn preclinical studies, IMA402 demonstrated...
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of...
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity –...
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”),...
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing...
Support, Research, and Saving Lives Remains Focus of First in Person Ovarian Cancer Canada Walk of Hope since 2019 File...
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D.,...
Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition elementThis novel system...
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model...
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development...